Fig. 3: Multivariate analysis of survival outcomes according to the Allo-HCT Refined ELN 2022 risk classification. | Blood Cancer Journal

Fig. 3: Multivariate analysis of survival outcomes according to the Allo-HCT Refined ELN 2022 risk classification.

From: Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)

Fig. 3

Overall survival (a) and leukemia-free survival (b). PTCY post-transplant cyclophosphamide, AML acute myeloid leukemia, MRD measurable residual disease, CR complete response.

Back to article page